497
Participants
Start Date
September 2, 2020
Primary Completion Date
March 10, 2021
Study Completion Date
March 29, 2021
Rivaroxaban
Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.
Placebo
Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.
Harlem Hospital Center, New York
NYC Health + Hospitals/Lincoln, The Bronx
Elmhurst Hospital Center, Elmhurst
Adult Medicine of Lake County, Mt. Dora
LCC Medical Research - Miami - BTC - PPDS, Miami
Invesclinic, LLC, Fort Lauderdale
Advanced Pulmonary Research Institute, Loxahatchee Groves
Clinical Research Institute, Inc - CRN - PPDS, Minneapolis
Providea Health Partners LLC, Evergreen Park
Woodland Research Northwest LLC - ERG - PPDS, Rogers
Village Health Partners - Plano - Hunt - PPDS, Plano
South Texas Allergy and Asthma Medical Professionals, San Antonio
Premier Family Physicians - Austin - Hunt - PPDS, Austin
Encompass Care, North Las Vegas
Science 37, Inc, Los Angeles
Allergy and Asthma Medical Group and Research Center - CRN - PPDS, San Diego
Riverside Medical Group - Circuit- PPDS, Secaucus
Boundary House Medical Centre, Sale
St Mary's Hospital - PPDS, London
Royal Free Hospital, London
Lead Sponsor
Gates Medical Research Institute
OTHER